Compare Grab Holdings Ltd. (GRAB) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Natera Inc. Common Stock — how do they compare? Grab Holdings Ltd. trades at $2.89 (market cap $12.19B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.7× Grab Holdings Ltd.'s market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Natera Inc. Common Stock for 0 Days on average.
| GRAB | NTRA | |
|---|---|---|
Market Cap | $12.19B | $57.03B |
Volume | 48,418,739 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $6.12 | $425.64 |
52-Week Low | $2.80 | $179.42 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $7.93B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $2.91, down 7.62% in the past 24 hours, with technical indicators showing bearish momentum. The company demonstrates strong fundamental improvement with revenue growing from $1.4B in 2022 to $3.37B in 2025 and achieving profitability with $268M net income. Recent developments include the $1.49B acquisition of Atome Financial and aggressive share repurchases, while management has shown confidence through significant insider buying.
GRAB presents a compelling turnaround story with accelerating revenue growth and recent profitability. The stock trades at reasonable valuations (P/E 27.09, P/S 3.65) with 92% analyst buy ratings. Key risks include integration challenges from the Atome acquisition and regional regulatory uncertainties in Southeast Asian markets.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
